Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
| Revenue (TTM) | $3.77B |
| Gross Profit (TTM) | $2.08B |
| EBITDA | $1.14B |
| Operating Margin | 2.84% |
| Return on Equity | 5.21% |
| Return on Assets | 3.31% |
| Revenue/Share (TTM) | $57.84 |
| Book Value | $155.78 |
| Price-to-Book | 2.43 |
| Price-to-Sales (TTM) | 9.59 |
| EV/Revenue | 11.22 |
| EV/EBITDA | 42.71 |
| Quarterly Earnings Growth (YoY) | -3.10% |
| Quarterly Revenue Growth (YoY) | 91.40% |
| Shares Outstanding | $98.19M |
| Float | $98.00M |
| % Insiders | 0.10% |
| % Institutions | 99.70% |
Volatility is currently contracting
MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m.
Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. 50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.
MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Examine the evolution of Waters' (WAT) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.
